𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kynurenines in Parkinson’s disease: therapeutic perspectives

✍ Scribed by Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei

Publisher
Springer
Year
2011
Tongue
English
Weight
245 KB
Volume
119
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Milestones in Parkinson's disease therap
Milestones in Parkinson's disease therapeutics
✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I

Stem cells in development of therapeutic
Stem cells in development of therapeutics for Parkinson's disease: A perspective
✍ Jiajie Xi; Su-Chun Zhang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

## Abstract Using Parkinson's disease as a prototype of neurodegenerative diseases, we propose applications of human stem cells in the development of therapeutics for neurodegenerative diseases. First, in vitro differentiation of human stem cells offers a versatile model for dissecting molecular in

Therapeutic directions for Parkinson's d
Therapeutic directions for Parkinson's disease
✍ Ira Shoulson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

## Abstract The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge t

Inositol is not therapeutic in Parkinson
Inositol is not therapeutic in Parkinson's Disease
✍ Alex Mishori; Joseph Levine; Esther Kahana; R. H. Belmaker 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Inositol 12 g per day was added to ongoing anti-Parkinson therapy in a controlled randomized cross-over design in nine patients. No therapeutic eect was found.